EA201891002A1 - Иммунологический анализ для определения расщепленного высокомолекулярного кининогена - Google Patents
Иммунологический анализ для определения расщепленного высокомолекулярного кининогенаInfo
- Publication number
- EA201891002A1 EA201891002A1 EA201891002A EA201891002A EA201891002A1 EA 201891002 A1 EA201891002 A1 EA 201891002A1 EA 201891002 A EA201891002 A EA 201891002A EA 201891002 A EA201891002 A EA 201891002A EA 201891002 A1 EA201891002 A1 EA 201891002A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- splitted
- determination
- immunological analysis
- kininogen
- molecular
- Prior art date
Links
- 102000010631 Kininogens Human genes 0.000 title 1
- 108010077861 Kininogens Proteins 0.000 title 1
- 230000001900 immune effect Effects 0.000 title 1
- 102000002261 High-Molecular-Weight Kininogen Human genes 0.000 abstract 3
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 abstract 3
- 238000003018 immunoassay Methods 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562243505P | 2015-10-19 | 2015-10-19 | |
| US201662335311P | 2016-05-12 | 2016-05-12 | |
| PCT/US2016/057640 WO2017070170A1 (en) | 2015-10-19 | 2016-10-19 | Immunoassay to detect cleaved high molecular weight kininogen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201891002A1 true EA201891002A1 (ru) | 2018-11-30 |
Family
ID=57233867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891002A EA201891002A1 (ru) | 2015-10-19 | 2016-10-19 | Иммунологический анализ для определения расщепленного высокомолекулярного кининогена |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10914747B2 (enExample) |
| EP (3) | EP3365685B1 (enExample) |
| JP (4) | JP6903648B2 (enExample) |
| KR (2) | KR102698737B1 (enExample) |
| CN (2) | CN113655228B (enExample) |
| AU (2) | AU2016340826C1 (enExample) |
| BR (1) | BR112018007842A2 (enExample) |
| CA (1) | CA3002747A1 (enExample) |
| CO (1) | CO2018004289A2 (enExample) |
| DK (1) | DK3365685T3 (enExample) |
| EA (1) | EA201891002A1 (enExample) |
| ES (2) | ES2857552T3 (enExample) |
| IL (2) | IL258637B2 (enExample) |
| MX (2) | MX2018004763A (enExample) |
| PL (2) | PL3839514T3 (enExample) |
| PT (1) | PT3365685T (enExample) |
| WO (1) | WO2017070170A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111044725B (zh) | 2013-01-20 | 2024-03-29 | 武田药品工业株式会社 | 缓激肽介导的病症的评估和治疗 |
| PT3060908T (pt) | 2013-10-21 | 2021-05-27 | Dyax Corp | Diagnóstico e tratamento de doenças autoimunes |
| KR20250066486A (ko) | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| JP6903648B2 (ja) | 2015-10-19 | 2021-07-14 | ダイアックス コーポレーション | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| US11525002B2 (en) | 2017-10-11 | 2022-12-13 | Board Of Regents, The University Of Texas System | Human PD-L1 antibodies and methods of use therefor |
| EP4501355A3 (en) | 2018-03-23 | 2025-04-30 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| CN119101158A (zh) | 2018-03-23 | 2024-12-10 | 得克萨斯州大学系统董事会 | 人pd-l2抗体及其使用方法 |
| CN117586412A (zh) | 2018-03-23 | 2024-02-23 | 得克萨斯州大学系统董事会 | 针对人pd-l1和pd-l2的双重特异性抗体及其使用方法 |
| WO2020004490A1 (ja) * | 2018-06-26 | 2020-01-02 | 協和キリン株式会社 | コンドロイチン硫酸プロテオグリカン－５に結合する抗体 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1312564C (en) | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
| US5047323A (en) * | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
| US4908431A (en) | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| KR960009766B1 (ko) | 1986-09-10 | 1996-07-24 | 니혼 소오끼 세이야꾸 가부시기가이샤 | 생리 활성물질 측정법 |
| US4882272A (en) | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
| US5025796A (en) | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1993003748A1 (en) | 1991-08-13 | 1993-03-04 | Temple University - Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0739355B1 (en) | 1994-01-11 | 2004-09-08 | Dyax Corporation | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| JPH1084995A (ja) * | 1996-09-12 | 1998-04-07 | Nippon Zoki Pharmaceut Co Ltd | 血液凝固第ｘｉｉ因子活性化法 |
| US5789261A (en) * | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
| US6242210B1 (en) | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
| JP4346798B2 (ja) * | 1999-08-19 | 2009-10-21 | 協和メデックス株式会社 | Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。 |
| US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| US7678541B2 (en) | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
| JP2002221519A (ja) * | 2001-01-29 | 2002-08-09 | Sysmex Corp | 抗凝固剤およびそれを用いた抗凝固剤処理方法 |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| US6913900B2 (en) * | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| ATE528014T1 (de) | 2002-06-07 | 2011-10-15 | Dyax Corp | Polypeptid mit modifizierten kunitz domains |
| WO2004005934A2 (en) | 2002-07-04 | 2004-01-15 | Oxford Glycosciences (Uk) Ltd | Toxicity markers |
| US20070003552A1 (en) | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| LT1981519T (lt) | 2005-12-29 | 2018-04-25 | Dyax Corp. | Proteazės slopinimas |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| US7625944B2 (en) | 2006-07-31 | 2009-12-01 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| JP2010510528A (ja) | 2006-11-22 | 2010-04-02 | ライフ テクノロジーズ コーポレーション | 自己免疫疾患のバイオマーカー |
| WO2009026334A2 (en) | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| EP2216651A4 (en) | 2007-10-18 | 2010-12-01 | Miyazaki Prefectural Ind Suppo | BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE |
| WO2009053050A1 (en) | 2007-10-22 | 2009-04-30 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| JP5348595B2 (ja) | 2008-07-07 | 2013-11-20 | 日本臓器製薬株式会社 | 線維筋痛症の検査法 |
| JP2012507723A (ja) | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| EP2369930A4 (en) | 2008-12-02 | 2012-10-03 | Joslin Diabetes Ct | METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ダイアックス コーポレーション | カリクレイン阻害剤による粘膜炎治療 |
| FR2942233B1 (fr) * | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre |
| KR101077275B1 (ko) | 2009-05-07 | 2011-10-27 | 한국기초과학지원연구원 | 당단백질의 당쇄화를 이용한 암 진단 방법 |
| JP5299179B2 (ja) | 2009-09-02 | 2013-09-25 | 株式会社リコー | 画像形成装置 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| CN102762203A (zh) | 2009-12-18 | 2012-10-31 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂的前药 |
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| EP2593121A2 (en) | 2010-07-13 | 2013-05-22 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| AU2011336345B2 (en) * | 2010-12-02 | 2016-07-07 | Becton, Dickinson And Company | Blood collection devices containing blood stabilization agent |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| AU2012267546B2 (en) | 2011-06-10 | 2015-12-24 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
| US9187749B2 (en) | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| FR2983215B1 (fr) | 2011-11-28 | 2013-12-20 | Univ Grenoble 1 | Dosage de la capacite de controle de c1inh |
| CN111044725B (zh) * | 2013-01-20 | 2024-03-29 | 武田药品工业株式会社 | 缓激肽介导的病症的评估和治疗 |
| US20140220552A1 (en) * | 2013-02-01 | 2014-08-07 | Becton, Dickinson And Company | Blood collection devices containing contact pathway inhibition additives |
| KR20250066486A (ko) * | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| PT3060908T (pt) | 2013-10-21 | 2021-05-27 | Dyax Corp | Diagnóstico e tratamento de doenças autoimunes |
| KR102424183B1 (ko) * | 2014-01-21 | 2022-07-26 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도 |
| JP6903648B2 (ja) * | 2015-10-19 | 2021-07-14 | ダイアックス コーポレーション | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| EP3390439B1 (en) | 2015-12-15 | 2025-03-12 | Takeda Pharmaceutical Company Limited | Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk |
| WO2021094587A1 (en) | 2019-11-13 | 2021-05-20 | eV-Technologies | Spin-wave based magnetic and/or electro-magnetic field sensing device for dc, rf and millimeter-wave applications |
| US20230072523A1 (en) | 2020-01-28 | 2023-03-09 | Orgenesis Inc. | Process and system for acellular therapy |
-
2016
- 2016-10-19 JP JP2018519871A patent/JP6903648B2/ja active Active
- 2016-10-19 EP EP16791171.8A patent/EP3365685B1/en active Active
- 2016-10-19 CA CA3002747A patent/CA3002747A1/en active Pending
- 2016-10-19 EP EP20209278.9A patent/EP3839514B1/en active Active
- 2016-10-19 KR KR1020187014261A patent/KR102698737B1/ko active Active
- 2016-10-19 ES ES16791171T patent/ES2857552T3/es active Active
- 2016-10-19 PL PL20209278.9T patent/PL3839514T3/pl unknown
- 2016-10-19 PT PT167911718T patent/PT3365685T/pt unknown
- 2016-10-19 US US15/769,237 patent/US10914747B2/en active Active
- 2016-10-19 DK DK16791171.8T patent/DK3365685T3/da active
- 2016-10-19 BR BR112018007842-5A patent/BR112018007842A2/pt active Search and Examination
- 2016-10-19 CN CN202110923341.6A patent/CN113655228B/zh active Active
- 2016-10-19 IL IL258637A patent/IL258637B2/en unknown
- 2016-10-19 CN CN201680069922.5A patent/CN108291917B/zh active Active
- 2016-10-19 KR KR1020247027973A patent/KR20240133761A/ko active Pending
- 2016-10-19 MX MX2018004763A patent/MX2018004763A/es unknown
- 2016-10-19 PL PL16791171T patent/PL3365685T3/pl unknown
- 2016-10-19 WO PCT/US2016/057640 patent/WO2017070170A1/en not_active Ceased
- 2016-10-19 EA EA201891002A patent/EA201891002A1/ru unknown
- 2016-10-19 EP EP23215946.7A patent/EP4354146A3/en active Pending
- 2016-10-19 IL IL312916A patent/IL312916A/en unknown
- 2016-10-19 ES ES20209278T patent/ES2973301T3/es active Active
- 2016-10-19 AU AU2016340826A patent/AU2016340826C1/en active Active
-
2018
- 2018-04-18 MX MX2023005689A patent/MX2023005689A/es unknown
- 2018-04-23 CO CONC2018/0004289A patent/CO2018004289A2/es unknown
-
2021
- 2021-01-05 US US17/141,690 patent/US12493047B2/en active Active
- 2021-06-23 JP JP2021104359A patent/JP7238027B2/ja active Active
-
2023
- 2023-01-30 AU AU2023200462A patent/AU2023200462B2/en active Active
- 2023-03-01 JP JP2023031415A patent/JP7640599B2/ja active Active
-
2025
- 2025-02-20 JP JP2025025949A patent/JP2025081553A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201891002A1 (ru) | Иммунологический анализ для определения расщепленного высокомолекулярного кининогена | |
| AU2019268150A1 (en) | Isotyping immunoglobulins using accurate molecular mass | |
| EA201892417A1 (ru) | Антитела, распознающие тау | |
| MA38632A1 (fr) | Anticorps anti-récepteur de transferrine et procédés d'utilisation | |
| MX388164B (es) | Anticuerpos y fragmentos anti-vista | |
| MX374652B (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco. | |
| WO2014165082A3 (en) | Antibodies and methods of detection | |
| EA201892412A1 (ru) | Антитела, распознающие тау | |
| MX2019001767A (es) | Anticuerpos monoclonales que se unen al dominio de union a lipidos de la proteina de la capside del virus de la hepatitis c (vhc). | |
| EA201792289A1 (ru) | Способы обнаружения агглютинации и композиции для их осуществления | |
| EA202190266A1 (ru) | Рекомбинантные захватывающие белки клеточной поверхности | |
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| EA201892325A1 (ru) | Композиции и способы детектирования белков клетки-хозяина | |
| HK1231555A1 (zh) | 生物标志物及其用途 | |
| EA201991464A1 (ru) | АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ | |
| EA201890739A1 (ru) | Анти-s100a8 для лечения лейкемии | |
| BR112018012679A2 (pt) | anticorpos contra complexos imunes que compreendem hepatotoxinas peptídicas cíclicas de cianobactéria | |
| MX2017004516A (es) | Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca. | |
| RU2012148244A (ru) | Способ диагностики онкологических заболеваний и иммуноферментный набор для его осуществления | |
| TR201902845T4 (tr) | Artritik durumların karakterize edilmesine yönelik bileşimler ve yöntemler. | |
| MX375897B (es) | Novedoso anticuerpo anti-presepsina. | |
| BR112018013381A2 (pt) | anticorpo especificamente ligante a antígenos derivados de miobacteria ou fragmento ligante a antígeno do mesmo | |
| EA201400571A1 (ru) | Специфичные к трансресвератролу антитела и их применение | |
| BR112016015537A2 (pt) | métodos e kits para detectar a presença de sequência polinucleotídea da e. histolytica em amostra | |
| EP2913675A3 (en) | GP2 isoforms and their use in autoantibody capture |